India GLP-1 Receptor Agonist Market Trends
The India GLP-1 receptor agonist market size was estimated at USD 110.55 million in 2024 and is projected to grow at a CAGR of 34.3% from 2025 to 2030. The market is driven by the rising incidence of chronic conditions such as type 2 diabetes and obesity, increasing R&D activities for novel therapeutics, patent expiry, and the entry of generic alternatives. According to the International Diabetes Federation report of 2024, 8.98 million adults are prone to diabetes, and approximately 185 million people will succumb to diabetes by 2050 in India.
India has witnessed a significant rise in metabolic disorders due to rapid urbanization, sedentary lifestyles, and poor dietary habits. With rising obesity rates, the demand for effective treatments is continuously increasing. GLP-1 receptor agonists are recognized as a promising therapeutic class for managing both obesity and type 2 diabetes by improving insulin sensitivity and promoting weight loss. These drugs have gained popularity due to their proven efficacy, making them a sought-after treatment for millions suffering from these chronic conditions in India.
The Ministry of Ayush, India, has implemented various initiatives to combat obesity and promote weight management through Ayurveda. The All India Institute of Ayurveda (AIIA) in New Delhi offers specialized treatments such as Panchakarma, Ayurvedic medicines, dietary guidelines, and practicing yoga. The Central Council for Research in Ayurvedic Sciences (CCRAS) is primarily involved in formulating, developing, and promoting Ayurvedic medicines. CCRAS conducts clinical trials to evaluate the safety and efficacy of Ayurvedic formulations and practices in managing lifestyle-related disorders such as diabetes, hypertension, obesity, and stress-related ailments.
The Ayurswasthya Yojana supports community-based healthcare initiatives to address obesity and related lifestyle disorders. Through strategic collaboration with the Council of Scientific and Industrial Research (CSIR), the program integrates traditional Ayurvedic knowledge with modern scientific approaches, thereby advancing research and improving the prevention and management of these conditions.
India GLP-1 Receptor Agonist Market Report Segmentation
This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the India GLP-1 receptor agonist market report based on product, application, route of administration, and distribution channel:
- Product Outlook (Revenue, USD Million, 2018 - 2030)
- Ozempic (semaglutide)
- Trulicity
- Mounjaro (tirzepatide)
- Wegovy (semaglutide)
- Rybelsus (oral semaglutide)
- Saxenda
- Victoza (liraglutide)
- Zepbound
- Other Products (SOLIQUA (lixisenatide), Bydureon)
- Application Outlook (Revenue, USD Million, 2018 - 2030)
- Type 2 Diabetes Mellitus
- Obesity
- Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Parenteral
- Oral
- Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Route of Administration
- 1.2.4. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. India GLP-1 Receptor Agonist Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- Chapter 4. India GLP-1 Receptor Agonist Market: Product Business Analysis
- 4.1. Product Market Share, 2024 & 2030
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Ozempic (semaglutide)
- 4.4.1. Ozempic (semaglutide) Market, 2018 - 2030 (USD Million)
- 4.5. Trulicity
- 4.5.1. Trulicity Market, 2018 - 2030 (USD Million)
- 4.6. Mounjaro (tirzepatide)
- 4.6.1. Mounjaro (tirzepatide) Market, 2018 - 2030 (USD Million)
- 4.7. Wegovy (semaglutide)
- 4.7.1. Wegovy (semaglutide)Market, 2018 - 2030 (USD Million)
- 4.8. Rybelsus (oral semaglutide)
- 4.8.1. Rybelsus (oral semaglutide) Market, 2018 - 2030 (USD Million)
- 4.9. Saxenda
- 4.9.1. Saxenda Market, 2018 - 2030 (USD Million)
- 4.10. Victoza (liraglutide)
- 4.10.1. Victoza (liraglutide) Market, 2018 - 2030 (USD Million)
- 4.11. Zepbound
- 4.11.1. Zepbound Market, 2018 - 2030 (USD Million)
- 4.12. Others
- 4.12.1. Others Market, 2018 - 2030 (USD Million)
- Chapter 5. India GLP-1 Receptor Agonist Market: Application Business Analysis
- 5.1. Application Market Share, 2024 & 2030
- 5.2. Application Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 5.4. Type 2 Diabetes Mellitus
- 5.4.1. Type 2 Diabetes Mellitus Market, 2018 - 2030 (USD Million)
- 5.5. Obesity
- 5.5.1. Obesity Market, 2018 - 2030 (USD Million)
- Chapter 6. India GLP-1 Receptor Agonist Market: Route of Administration Business Analysis
- 6.1. Route of Administration Market Share, 2024 & 2030
- 6.2. Route of Administration Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
- 6.4. Parenteral
- 6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
- 6.5. Oral
- 6.5.1. Oral Market, 2018 - 2030 (USD Million)
- Chapter 7. India GLP-1 Receptor Agonist Market: Distribution Channel Business Analysis
- 7.1. Distribution Channel Market Share, 2024 & 2030
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
- 7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
- 7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
- 7.6. Online Pharmacies
- 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
- Chapter 8. India GLP-1 Receptor Agonist Market: Country Estimates & Trend Analysis
- 8.1. Country Market Share Analysis, 2024 & 2030
- 8.2. Country Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
- 8.4. India
- 8.4.1. India
- 8.4.1.1. Key Country Dynamics
- 8.4.1.2. Target Disease Prevalence
- 8.4.1.3. Regulatory Framework
- 8.4.1.4. Reimbursement Framework
- 8.4.1.5. India GLP-1 Receptor Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. AstraZeneca
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. Novo Nordisk A/S
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. Eli Lilly and Co
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. Biocon
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. Sanofi
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. Glenmark Pharmaceuticals Ltd.
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. Cipla
- 9.5.7.1. Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Product Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. Sun Pharmaceuticals Industries Ltd
- 9.5.8.1. Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Product Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.9. Zydus Group
- 9.5.9.1. Overview
- 9.5.9.2. Financial Performance
- 9.5.9.3. Product Benchmarking
- 9.5.9.4. Strategic Initiatives
- 9.5.10. Lupin
- 9.5.10.1. Overview
- 9.5.10.2. Financial Performance
- 9.5.10.3. Product Benchmarking
- 9.5.10.4. Strategic Initiatives
- 9.5.11. Dr. Reddy’s Laboratories Ltd
- 9.5.11.1. Overview
- 9.5.11.2. Financial Performance
- 9.5.11.3. Product Benchmarking
- 9.5.11.4. Strategic Initiatives
- 9.5.12. Alkem
- 9.5.12.1. Overview
- 9.5.12.2. Financial Performance
- 9.5.12.3. Product Benchmarking
- 9.5.12.4. Strategic Initiatives
- 9.5.13. Piramal Pharma Limited
- 9.5.13.1. Overview
- 9.5.13.2. Financial Performance
- 9.5.13.3. Product Benchmarking
- 9.5.13.4. Strategic Initiatives
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook